After lengthy discussions with Roswell Park, AIM has determined that it is not in its stockholders’ best interests to relinquish “Third-Party Beneficiary” rights to any of AIM’s pre-existing Intellectual Property without appropriate compensation and licensing terms. This business decision has created an impasse which means AIM has no current plans to move forward with certain planned — but not yet initiated — trials at Roswell Park. Additionally, unlike pancreatic cancer and advanced recurrent ovarian cancer, these previous planned Roswell Park studies are not on the Company’s near-term critical path for future New Drug Applications, and will only become a priority after the Company accomplishes its goals related to pancreatic cancer and advanced recurrent ovarian cancer. For more information, please see the Company Presentation furnished herewith as Exhibit 99.1.

Cautionary Statement

This Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth herein speak only as of the date hereof. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and the presentation furnished as Exhibit 99.1 hereto sets forth the Company’s anticipated future activities. These planned activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Some of the world’s largest pharmaceutical companies and medical institutions are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that our actions toward proving this will be given first priority or that another treatment that eventually proves capable will not make our efforts ultimately unproductive. The Company recognizes that all cancer centers, like all medical facilities, must make the pandemic their priority. Therefore, there is the potential for delays in clinical trial enrollment and reporting in ongoing studies. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the presentation. In addition, many countries, including Argentina, are dealing with COVID-19 outbreaks and have made that their primary focus. The Company believes that this may be delaying its commercialization of Ampligen in Argentina until COVID-19 is more under control. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.